Figure 6.
Intrapancreatic 8803 synergizes with dual checkpoint blockade to prolong survival in mT4-LA independent of chemotherapy. (A) Implantation and treatment schedule. (B–D) Survival of mice bearing orthotopic and subcutaneous mT4-LA treated as described in figure part A, with n=5–10 mice per group. (E) Mice bearing only orthotopic mT4-LA (0.35×105 cells) were treated as described in figure part A with additional standard of care chemotherapy consisting of gemcitabine (120 mg/kg) and nab-paclitaxel (120 mg/kg) (Gem/nP) administered on days 10 and 22 in indicated groups. Longitudinal tumor growth by IVIS imaging and overall survival are shown. (F) Survival data associated with images presented in figure part E. Data are cumulative of two independent experiments each with 5–10 mice per group. (G) A single mouse cured by 8803 + αCTLA-4/αPD-1 in figure part E was rechallenged with 0.35×106 mT4-LA cells as previously described, in parallel with five naïve B6 albino mice. Tumor regression is shown via IVIS imaging. Statistical significance was calculated using the Log-rank Mantel-Cox test. *P<0.05, **p<0.01, ***p<0.001, ****p<0.0001. ns, not significant.